Cema-cel for high-risk lymphoma after first treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these types of lymphoma: diffuse large B-cell, high-grade B-cell, or primary mediastinal B-cell lymphoma.
- You must have completed a full course of standard first-line treatment (like R-CHOP or similar) and not received any other treatments.
- After your first treatment, your PET/CT scan must show that you are in complete remission or have a partial remission that is safe to watch.
- A special blood test (Foresight CLARITY MRD) must find tiny amounts of cancer cells left in your body.
- You must be 18 years or older, in good overall health (ECOG 0 or 1), and have adequate organ function.
- You cannot have had any prior treatment that targets CD19, or have active autoimmune disease, serious infections, or another cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests whether the CAR-T cell therapy axicabtagene ciloleucel (a type of immunotherapy made from your own immune cells) can be effective as a first treatment for people with aggressive large B-cell lymphoma that hasn't responded well after two rounds of chemoimmunotherapy. It's designed for patients with high-risk features who might need a stronger approach early on.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.